Background: Photodynamic therapy (PDT) is an excellent treatment option for actinic keratosis. However the side effects lead to an impairment of the patients' quality of life. Objectives: To evaluate the impact of PDT on patients' quality of life and to determine the frequency and intensity of side effects over the course of 4 weeks post PDT. Patients and Methods: 22 patients with actinic keratosis in the face were included into this prospective study. Pain was measured using a visual analog scale immediately and 8 h after PDT. The Dermatology Life Quality Index (DLQI) was assessed at screening, after treatment as well as 2 and 4 weeks after PDT. The physician and patient evaluated the intensity of side effects during the treatment, 2 and 4 weeks post PDT. Additionally, the patient documented side effects daily from the 1st to the 14th day after PDT and on day 28 post PDT, using a diary. Results: We observed a significant (p < 0.001) increase in the DLQI from 1.6 ± 1.7 prior to PDT to 7.3 ± 4.9 post PDT. The DLQI normalized in the following 4 weeks. Immediately and 8 h after PDT mean pain was 4.3 ± 2.5 and 2.3 ± 2.1. Side effects documented by the patients were erythema (100%), pain, burning, edema (90.9%), itching (86.4%), scaling (81.8%) and pustules (59.1%). No scar formation, hyper-/hypopigmentation or infections were observed. Conclusion: PDT has a significant temporary impact on patients' DLQI. Transitory side effects are common and show typical kinetics.

Keywords:
Actinic keratosis, Photodynamic therapy, Side effects, Pain, Dermatology Life Quality Index, Quality of life
1.
Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA; International Society for Photodynamic Therapy in Dermatology: Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007;56:125-143.
2.
Kondo M, Hirota N, Takaoka T, Kajiwara M: Heme-biosynthetic enzyme activities and porphyrin accumulation in normal liver and hepatoma cell lines of rat. Cell Biol Toxicol 1993;9:95-105.
3.
Noodt BB, Berg K, Stokke T, Peng Q, Nesland JM: Apoptosis and necrosis induced with light and 5-aminolaevulinic acid-derived protoporphyrin IX. Br J Cancer 1996;74:22-29.
4.
Dirschka T, Radny P, Dominicus R, Mensing H, Bruning H, Jenne L, Karl L, Sebastian M, Oster-Schmidt C, Klovekorn W, Reinhold U, Tanner M, Grone D, Deichmann M, Simon M, Hubinger F, Hofbauer G, Krahn-Senftleben G, Borrosch F, Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Honigsmann H, Wernicke-Panten K, Helwig C, Foguet M, Schmitz B, Lubbert H, Szeimies RM; AK-CT002 Study Group: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012;166:137-146.
5.
Gholam P, Weberschock T, Denk K, Enk A: Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology 2011;222:358-362.
6.
Grapengiesser S, Ericson M, Gudmundsson F, Larko O, Rosen A, Wennberg AM: Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002;27:493-497.
7.
Lehmann P: Side effects of topical photodynamic therapy (in German). Hautarzt 2007;58:597-603.
8.
Gholam P, Denk K, Sehr T, Enk A, Hartmann M: Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J Am Acad Dermatol 2010;63:213-218.
9.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
10.
Steinbauer J, Koller M, Kohl E, Karrer S, Landthaler M, Szeimies RM: Quality of life in health care of non-melanoma skin cancer - results of a pilot study. J Dtsch Dermatol Ges 2011;9:129-135.
11.
Hadley J, Tristani-Firouzi P, Hull C, Florell S, Cotter M, Hadley M: Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol Surg 2012;38:722-727.
12.
Lindeburg KE, Brogaard HM, Jemec GB: Pain and photodynamic therapy. Dermatology 2007;215:206-208.
13.
Esmann S, Jemec GB: Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat 2007;18:53-58.
14.
Valentine RM, Ibbotson SH, Brown CT, Wood K, Moseley H: A quantitative comparison of 5-aminolaevulinic acid- and methyl aminolevulinate-induced fluorescence, photobleaching and pain during photodynamic therapy. Photochem Photobiol 2011;87:242-249.
15.
Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, de Berker D, Dummer R, Kerrouche N, Villemagne H: A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008;22:1302-1311.
16.
Morton CA, McKenna KE, Rhodes LE; British Association of Dermatologists Guidelines and Audit Subcommittee and the British Photodermatology Group: Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008;159:1245-1266.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.